Therapeutic use of microRNA-181a in the adoptive immunotherapy of cancer

ABSTRACT: The generation of highly-reactive T lymphocytes against tumor-associated antigens remains an obstacle for effective adoptive immunotherapy of cancer. Recently, we found that microRNA-181a (miR-181a) acts as an intrinsic modulator of T cell antigen sensitivity in a transgenic T cell line in vitro. This molecule is part of a growing family of evolutionarily selected small interfering RNA that control gene expression at the posttranscriptional level by targeting messenger RNA (mRNA) for degradation or translational repression. Here, we explored the use of miR-181a to improve anti-tumor T cell responsiveness against weakly immunogenic tumor-associated antigens. We found that genetic engineering of T lymphocytes with miR-181a dramatically augmented the function of poorly responsive human tumor-

ORGANISM(S): Homo sapiens

SUBMITTER: Nicholas Restifo 

PROVIDER: E-GEOD-9240 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress